Get all your news in one place.
100's of premium titles.
One app.
Start reading
The Independent UK
The Independent UK
National
The Associated Press

Pfizer amps up push into obesity treatments with $4.9B deal for Metsera

Pfizer is doubling down on obesity treatments by spending $4.9 billion on the development-stage drugmaker Metsera.

The COVID-19 vaccine and treatment maker said early Monday that it will pay $47.50 per share in cash for each Metsera share. That represents a premium of more than 42% to Metsera’s closing price Friday.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.